Becton Dickinson Stock Rises as FDA Alerts on Recalled Ampules

Key Points

The FDA issued an early alert about Becton Dickinson convenience kits containing recalled sodium chloride ampules from Huons Co., Ltd., initially recalled by Elevaris Medical Devices.
BD sent a letter on August 10 instructing healthcare providers to stop using the affected ampules, quarantine stock, and destroy the ampules upon opening trays in sterile environments.
Potential health risks include exposure to endotoxins, microorganisms, or foreign particles, which could cause severe reactions, though no deaths or serious injuries have been reported as of July 29.
BDX stock rose about 3% on Wednesday, trading above key moving averages, but the RSI at 74.01 signals overbought conditions.
Analysts maintain a Buy consensus with an average price target of $184.20, with recent price target raises from RBC Capital and Citigroup.

Get Becton Dickinson & Alerts

Weekly insights + SMS alerts

If you're a healthcare provider who uses Becton Dickinson's convenience kits, you might want to check what's inside. The U.S. Food and Drug Administration announced that Becton Dickinson and Company (BDX) alerted customers to correct specific convenience kits by removing recalled sodium chloride ampules manufactured by Huons Co., Ltd., which Elevaris Medical Devices initially recalled.

Corrective Measures And Usage Guidelines

Convenience kits contain various surgical instruments, dressings, and pharmaceutical components designed for surgical procedures. On August 10, BD sent a letter instructing healthcare providers to stop using the specific sodium chloride ampules found in the affected kits.

Facilities must quarantine their stock until they receive over-labels. Medical staff can safely use all other components within these surgical and procedural trays. The company advises customers to label the impacted kits without covering essential regulatory details.

Once they open a tray in a sterile environment, staff must immediately remove and destroy the recalled ampule to preserve the sterility of the remaining items.

Potential Health Risks And Patient Monitoring

Patients could face exposure to endotoxins, microorganisms, or foreign particles. These contaminants can induce severe reactions, including infections, micro-clots, systemic inflammatory responses, and organ failure. BD reported no deaths or serious injuries connected to this defect as of July 29.

Patients treated with the affected ampules require no specific follow-up if they remain asymptomatic.

Stock Performance and Technical Analysis

Becton Dickinson stock rose about 3% Wednesday as healthcare stocks led the market. The Nasdaq fell 0.22%, while the S&P 500 gained 0.22%. The move extends the stock's recent rebound and suggests sector rotation continues to support BDX.

Becton Dickinson trades 7.7% above its 20-day simple moving average of $172.90 and 8.6% above its 200-day SMA of $171.42. It is also 16.5% above its 50-day SMA of $159.78 and 20% above its 100-day SMA of $155.12.

However, the relative strength index stands at 74.01. An RSI above 70 generally indicates overbought conditions and raises the risk of a near-term pause or pullback.

The longer-term technical picture remains mixed. The stock formed a death cross in March when its 50-day SMA fell below its 200-day SMA. BDX has since reclaimed both averages, but the bearish crossover has not yet reversed.

Resistance sits near $196, while support is around $153.50.

Becton Dickinson Analyst Outlook

The stock carries a Buy consensus rating with an average price forecast of $184.20.

RBC Capital maintained a Sector Perform rating and raised its price forecast to $190 on August 13. Citigroup maintained a Buy rating and raised its price forecast to $204 on August 7. RBC Capital had previously raised its price forecast to $180 on August 7.

Becton Dickinson Price Action

BDX Stock Price Activity: Becton Dickinson shares were up 3.02% at $186.23 at the time of publication on Wednesday, according to market data.

Stock Market News

Becton Dickinson Stock Rises as FDA Alerts on Recalled Ampules

Get Becton Dickinson & Alerts

Corrective Measures And Usage Guidelines

Potential Health Risks And Patient Monitoring

Stock Performance and Technical Analysis

Becton Dickinson Analyst Outlook

Becton Dickinson Price Action

More News

3 AI stocks to buy before December 2026

Watch this before August 31st

$44 Trillion “Super Convergence:” Elon’s Biggest Move EVER?

The Tech IPO Set to Be 41X bigger than the Microsoft, Google, and Amazon IPOs combined

Elon Musk Drops Bombshell During SpaceX Earnings Call

The Free Guide Every New Options Trader Needs

Google's secret $99 billion profit

He turned $12K into $1.65M without touching Apple or Tesla

Get Becton Dickinson & Alerts

Featured Articles

Iran Weighs Strikes on US Targets in Europe as NATO Vows to 'Address Any Threat'

Once you see it, you can't unsee it (Ad)

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Futures Edge Higher as Trump Nixes Iran Talks, Fed Minutes Loom: KEYS, MRCY, SKHY in Focus

SK Hynix's $29 Billion Buyback: A Bold Bet Against AI Spending Fears

Trade the "Fav-4" for weekly income (Ad)

Micron Stock Rebounds After Cathie Wood's Memory Warning

The Iran War Sent Gas Prices Skyrocketing, but the US Now Faces a Diesel Problem

Iran Weighs Strikes on US Targets in Europe as NATO Vows to 'Address Any Threat'

Once you see it, you can't unsee it (Ad)

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Futures Edge Higher as Trump Nixes Iran Talks, Fed Minutes Loom: KEYS, MRCY, SKHY in Focus

SK Hynix's $29 Billion Buyback: A Bold Bet Against AI Spending Fears

Trade the "Fav-4" for weekly income (Ad)

Micron Stock Rebounds After Cathie Wood's Memory Warning

The Iran War Sent Gas Prices Skyrocketing, but the US Now Faces a Diesel Problem